{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:04:54Z","timestamp":1784739894760,"version":"3.55.0"},"reference-count":40,"publisher":"IMR Press","issue":"11","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hunan Provincial Health Commission Foundation of China","award":["20257169"],"award-info":[{"award-number":["20257169"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: Programmed death-ligand 1 (PD-L1) partners with specificity Protein 1 (SP1) or signal transducer and activator of transcription 3 (STAT3) to modulate the transcription of growth arrest-specific 6 (GAS6) and early growth response protein 1 (EGR1), necessitating mediators to avoid feedback. Based on binding and stemness data, high mobility group A1 (HMGA1) and Small Mother Against Decapentaplegic3 (SMAD3) were identified as potential mediators in this context. While the SMAD3\u2013P300\u2013STAT3 complex facilitates SMAD3\u2013STAT3 crosstalk, it remains unclear whether the PD-L1\u2013HMGA1\u2013SP1 or PD-L1\u2013SMAD3\u2013SP1 complexes bind to GAS6 and EGR1 promoters to regulate their transcription. Methods: MG63 osteosarcoma cells and SW620 colon cancer cells with unidentified nuclear PD-L1 function were chosen for our study. Chromatin immunoprecipitation and co-immunoprecipitation assays were performed to evaluate SP1, HMGA1, SMAD3, STAT3, P300 and PD-L1 (also denoted CD274) enrichment at the GAS6 and EGR1 promoters; the existence of the PD-L1\u2013(HMGA1 or SMAD3)\u2013SP1 complexes; whether P300 binds to STAT3; and whether HMGA1 and SMAD3 bind to P300. The alterations in GAS6, EGR1 and PD-L1 mRNA levels after their combined over-expression and\/or knockdown were assessed via qPCR. Two representative target genes identified via PD-L1 chromatin immunoprecipitation (ChIP)-seq were examined to determine whether HMGA1 and SMAD3 were enriched at their promoters. Results: PD-L1, HMGA1, SMAD3, SP1, P300 and STAT3 were enriched at GAS6 and EGR1 promoters in two cell lines. HMGA1 or SMAD3 antibody pulled down PD-L1 and SP1; PD-L1 antibody pulled down HMGA1, SMAD3 and SP1; P300 antibody pulled down STAT3; and, surprisingly, HMGA1 and SMAD3 antibodies pulled down P300. Combined over-expression or knockdown significantly altered GAS6, EGR1 and PD-L1 mRNA levels. PD-L1 ChIP-seq indicated 114 target genes, among which PD-L1 and beta-transducin repeat containing E3 ubiquitin protein ligase (BTRC) were chosen to verify the promoter enrichment of HMGA1 and SMAD3. Conclusion: Our study provides initial evidence that PD-L1 might form HMGA1- and SMAD3-dependent complexes to bind the GAS6, EGR1 and CD274 promoters, thus modulating the transcription of GAS6, EGR1 and PD-L1 mRNA in cancer and sarcoma cells.<\/jats:p>","DOI":"10.31083\/fbl46743","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T09:55:11Z","timestamp":1765014911000},"source":"Crossref","is-referenced-by-count":2,"title":["HMGA1\/SMAD3 Promoter Complex Mediates PD-L1-Dependent Transcriptional Regulation of GAS6, EGR1 and PD-L1"],"prefix":"10.31083","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0091-1312","authenticated-orcid":true,"given":"Hui","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Pathology, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya Medical School, Central South University, 410073 Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-0221","authenticated-orcid":true,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya Medical School, Central South University, 410073 Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5027-7747","authenticated-orcid":true,"given":"Pingping","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya Medical School, Central South University, 410073 Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Chen L. PD-L1 and the dawn of modern cancer immunotherapy. Nature Medicine. 2025; 31: 1378.","DOI":"10.1038\/s41591-025-03698-4"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Xiong W, Gao Y, Wei W, Zhang J. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends in Cancer. 2021; 7: 837\u2013846.","DOI":"10.1016\/j.trecan.2021.03.003"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2016; 27: 409\u2013416.","DOI":"10.1093\/annonc\/mdv615"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Nieto C, Miller B, Alzofon N, Chimed T, Himes J, Joshi M, et al. The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma. Journal of the National Cancer Institute. 2023; 115: 1392\u20131403.","DOI":"10.1093\/jnci\/djad126"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. Journal of Hematology & Oncology. 2022; 15: 24.","DOI":"10.1186\/s13045-022-01242-2"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Tian Y, Qi H, Zhu N, Yan X, Guo L, Wang L, et al. An IL-6-induced STAT3-to-PI3K signaling switch potently drives PD-L1 transcription in cancer stem cells of colorectal cancer. Science Bulletin. 2025.  (in press)","DOI":"10.1016\/j.scib.2025.07.013"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nature Cell Biology. 2020; 22: 1064\u20131075.","DOI":"10.1038\/s41556-020-0562-4"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Guo X, Sunil C, Adeyanju O, Parker A, Huang S, Ikebe M, et al. PD-L1 mediates lung fibroblast to myofibroblast transition through Smad3 and \u03b2-catenin signaling pathways. Scientific Reports. 2022; 12: 3053.","DOI":"10.1038\/s41598-022-07044-3"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Yu J, Zhuang A, Gu X, Hua Y, Yang L, Ge S, et al. Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis. Cell Discovery. 2023; 9: 33.","DOI":"10.1038\/s41421-023-00521-7"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Du W, Zhu J, Zeng Y, Liu T, Zhang Y, Cai T, et al. KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6\/MerTK signaling pathway. Cell Death and Differentiation. 2021; 28: 1284\u20131300.","DOI":"10.1038\/s41418-020-00651-5"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu JM, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nature Cell Biology. 2020; 22: 1264\u20131275.","DOI":"10.1038\/s41556-020-0575-z"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Tao LH, Zhou XR, Li FC, Chen Q, Meng FY, Mao Y, et al. A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer. Cancer Immunology, Immunotherapy: CII. 2017; 66: 309\u2013318.","DOI":"10.1007\/s00262-016-1936-0"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Miyazawa M, Yamamoto Y, Katayama K, Sugimoto Y, Noguchi K. Kaposi\u2019s sarcoma-associated herpesvirus replication and transcription activator protein activates CD274\/PD-L1 gene promoter. Cancer Science. 2023; 114: 1718\u20131728.","DOI":"10.1111\/cas.15673"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Kimura K, Jackson TLB, Huang RCC. Interaction and Collaboration of SP1, HIF-1, and MYC in Regulating the Expression of Cancer-Related Genes to Further Enhance Anticancer Drug Development. Current Issues in Molecular Biology. 2023; 45: 9262\u20139283.","DOI":"10.3390\/cimb45110580"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Wang Z, Li MY, Zhang ZH, Zuo HX, Wang JY, Xing Y, et al. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1\u03b1 and STAT3 in human colon cancer cells. Pharmacological Research. 2020; 155: 104727.","DOI":"10.1016\/j.phrs.2020.104727"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"He Y, Zhu M, Lai X, Zhang H, Jiang W. The roles of PD-L1 in the various stages of tumor metastasis. Cancer Metastasis Reviews. 2024; 43: 1475\u20131488.","DOI":"10.1007\/s10555-024-10189-4"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Aiello A, Pandini G, Sarfstein R, Werner H, Manfioletti G, Vigneri R, et al. HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. European Journal of Cancer (Oxford, England: 1990). 2010; 46: 1919\u20131926.","DOI":"10.1016\/j.ejca.2010.02.050"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K. Tenascin-C upregulation by transforming growth factor-beta in human dermal fibroblasts involves Smad3, Sp1, and Ets1. Oncogene. 2004; 23: 1656\u20131667.","DOI":"10.1038\/sj.onc.1207064"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Wei F, Zhang T, Deng SC, Wei JC, Yang P, Wang Q, et al. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways. Cancer Letters. 2019; 450: 1\u201313.","DOI":"10.1016\/j.canlet.2019.02.022"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Junk DJ, Bryson BL, Smigiel JM, Parameswaran N, Bartel CA, Jackson MW. Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling. Oncogene. 2017; 36: 4001\u20134013.","DOI":"10.1038\/onc.2017.33"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Wang G, Yu Y, Sun C, Liu T, Liang T, Zhan L, et al. STAT3 selectively interacts with Smad3 to antagonize TGF-\u03b2 signalling. Oncogene. 2016; 35: 4388\u20134398.","DOI":"10.1038\/onc.2015.446"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Itoh Y, Saitoh M, Miyazawa K. Smad3-STAT3 crosstalk in pathophysiological contexts. Acta Biochimica et Biophysica Sinica. 2018; 50: 82\u201390.","DOI":"10.1093\/abbs\/gmx118"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Peng M, Fan S, Li J, Zhou X, Liao Q, Tang F, et al. Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K\/AKT and Raf\/MEK\/ERK pathways in tongue squamous cell carcinoma. Genes & Nutrition. 2022; 17: 3.","DOI":"10.1186\/s12263-022-00705-y"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Langmead B, Wilks C, Antonescu V, Charles R. Scaling read aligners to hundreds of threads on general-purpose processors. Bioinformatics (Oxford, England). 2019; 35: 421\u2013432.","DOI":"10.1093\/bioinformatics\/bty648"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Ohbayashi N, Ikeda O, Taira N, Yamamoto Y, Muromoto R, Sekine Y, et al. LIF- and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K\/Akt activation. Biological & Pharmaceutical Bulletin. 2007; 30: 1860\u20131864.","DOI":"10.1248\/bpb.30.1860"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Zhang Q, Zhang K, Zou Y, Perna A, Wang Y. A quantitative study on the in vitro and in vivo acetylation of high mobility group A1 proteins. Journal of the American Society for Mass Spectrometry. 2007; 18: 1569\u20131578.","DOI":"10.1016\/j.jasms.2007.05.020"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Ihn H, Yamane K, Asano Y, Jinnin M, Tamaki K. Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology (Oxford, England). 2006; 45: 157\u2013165.","DOI":"10.1093\/rheumatology\/kei124"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Yu J, Qin B, Moyer AM, Nowsheen S, Tu X, Dong H, et al. Regulation of sister chromatid cohesion by nuclear PD-L1. Cell Research. 2020; 30: 590\u2013601.","DOI":"10.1038\/s41422-020-0315-8"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Beishline K, Azizkhan-Clifford J. Sp1 and the \u2019hallmarks of cancer\u2019. The FEBS Journal. 2015; 282: 224\u2013258.","DOI":"10.1111\/febs.13148"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Chang KY, Huang CT, Hsu TI, Hsu CC, Liu JJ, Chuang CK, et al. Stress stimuli induce cancer-stemness gene expression via Sp1 activation leading to therapeutic resistance in glioblastoma. Biochemical and Biophysical Research Communications. 2017; 493: 14\u201319.","DOI":"10.1016\/j.bbrc.2017.09.095"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Chen Z, Xiang L, Li L, Ou H, Fang Y, Xu Y, et al. TGF-\u03b21 induced deficiency of linc00261 promotes epithelial-mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3. Journal of Translational Medicine. 2022; 20: 75.","DOI":"10.1186\/s12967-022-03276-z"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Schwachtgen JL, Campbell CJ, Braddock M. Full promoter sequence of human early growth response factor-1 (Egr-1): demonstration of a fifth functional serum response element. DNA Sequence: the Journal of DNA Sequencing and Mapping. 2000; 10: 429\u2013432.","DOI":"10.3109\/10425170009015615"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Carvajal IM, Baron RM, Perrella MA. High-mobility group-I\/Y proteins: Potential role in the pathophysiology of critical illnesses. Critical Care Medicine. 2002; 30: S36\u2013S42.","DOI":"10.1097\/00003246-200201001-00005"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Hou T, Ray S, Lee C, Brasier AR. The STAT3 NH2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain. The Journal of Biological Chemistry. 2008; 283: 30725\u201330734.","DOI":"10.1074\/jbc.M805941200"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Frischknecht L, Britschgi C, Galliker P, Christinat Y, Vichalkovski A, Gstaiger M, et al. BRAF inhibition sensitizes melanoma cells to \u03b1-amanitin via decreased RNA polymerase II assembly. Scientific Reports. 2019; 9: 7779.","DOI":"10.1038\/s41598-019-44112-7"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Lee TI, Wyrick JJ, Koh SS, Jennings EG, Gadbois EL, Young RA. Interplay of positive and negative regulators in transcription initiation by RNA polymerase II holoenzyme. Molecular and Cellular Biology. 1998; 18: 4455\u20134462.","DOI":"10.1128\/MCB.18.8.4455"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Moon Y, Cho H, Kim J, Song S, Yeon Park J, Young Min J, et al. Self-Assembled Peptide-Derived Proteolysis-Targeting Chimera (PROTAC) Nanoparticles for Tumor-Targeted and Durable PD-L1 Degradation in Cancer Immunotherapy. Angewandte Chemie (International Ed. in English). 2025; 64: e202414146.","DOI":"10.1002\/anie.202414146"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Deng L, Qian G, Zhang S, Zheng H, Fan S, Lesinski GB, et al. Inhibition of mTOR complex 1\/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced \u03b2-TrCP degradation. Oncogene. 2019; 38: 6270\u20136282.","DOI":"10.1038\/s41388-019-0877-4"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Lee JY, Kim KJ, Park W, Seo J, Kang M, Jung EH, et al. Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK\/T-cell lymphoma. Blood Cancer Journal. 2025; 15: 108.","DOI":"10.1038\/s41408-025-01313-w"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Aguilera TA, Giaccia AJ. Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2017; 23: 2928\u20132933.","DOI":"10.1158\/1078-0432.CCR-17-0189"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/30\/11\/10.31083\/FBL46743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T09:56:01Z","timestamp":1765014961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/30\/11\/10.31083\/FBL46743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"alternative-id":["S2768-6701(25)01901-X"],"URL":"https:\/\/doi.org\/10.31083\/fbl46743","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"article-number":"46743"}}